EUVIMEDEUVIMED entdecken
Crossref

Comparison of ATRA-Arsenic Trioxide and ATRAIdarubicin in Patients with Acute Promyelocytic Leukemia

Serhat Çelik, Ali Ünal, Ruveyda Şahin, Zeynep Tuğba Güven, Mustafa Baydar, Muzaffer Keklik, Mustafa Çetin, Leylagül Kaynar

LLM Dergi · 2022

DOI: 10.5578/llm.20229703 ↗

Kurz gefasst

Fachartikel in der Zeitschrift LLM Dergi, 2022. Verfasst von Serhat Çelik und 7 weiteren Autor:innen. Die Arbeit wurde bisher 1-mal zitiert (Crossref).

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Zitieren

APA

Çelik, S., Ünal, A., Şahin, R., Güven, Z. T., Baydar, M., Keklik, M., Çetin, M., & Kaynar, L. (2022). Comparison of ATRA-Arsenic Trioxide and ATRAIdarubicin in Patients with Acute Promyelocytic Leukemia. LLM Dergi. https://doi.org/10.5578/llm.20229703

Vancouver

Çelik S, Ünal A, Şahin R, Güven ZT, Baydar M, Keklik M, et al. Comparison of ATRA-Arsenic Trioxide and ATRAIdarubicin in Patients with Acute Promyelocytic Leukemia. LLM Dergi. 2022. doi:10.5578/llm.20229703

BibTeX
@article{elik2022,
  author = {Çelik, Serhat and Ünal, Ali and Şahin, Ruveyda and Güven, Zeynep Tuğba and Baydar, Mustafa and Keklik, Muzaffer and Çetin, Mustafa and Kaynar, Leylagül},
  title = {Comparison of ATRA-Arsenic Trioxide and ATRAIdarubicin in Patients with Acute Promyelocytic Leukemia},
  journal = {LLM Dergi},
  year = {2022},
  doi = {10.5578/llm.20229703}
}
Kostenlos starten →